Is IXSBF or JEPQ a better dividend investment in 2026?

IXSBF currently yields 2000000.00% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: IXSBF offers higher current income.

What is the dividend yield difference between IXSBF and JEPQ?

IXSBF has a forward dividend yield of 2000000.00% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 1999988.90 percentage points.

Home › Compare › IXSBF vs JEPQ

IXSBF vs JEPQ: Dividend Comparison 2026

IXSBF yields 2000000.00% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IXSBF wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IXSBF

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full IXSBF calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — IXSBF vs JEPQ

📍 IXSBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IXSBF	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IXSBF + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IXSBF pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IXSBF

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, IXSBF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IXSBF + JEPQ for your $10,000?

IXSBF: 50%JEPQ: 50%

100% JEPQ50/50100% IXSBF

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IXSBF buys

JEPQ buys

No recent congressional trades found for IXSBF or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIXSBFJEPQ

Forward yield	2000000.00% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.879226400974806e+39M	$44.8K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$2,152.59
Total dividends collected	$4.879195005460081e+39M	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: IXSBF vs JEPQ ($10,000, DRIP)

Year	IXSBF Portfolio	IXSBF Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,930	$1,110.39	+$200.00M → IXSBF
2	$3,738,731,768,458	$3,738,517,757,009.35	$14,133	$1,224.34	+$3738731.75M → IXSBF
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$16,632	$1,340.46	+$65315062866.91M → IXSBF
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$19,454	$1,457.97	+$1066400830062625.00M → IXSBF
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$22,626	$1,576.08	+$16272182796453826560.00M → IXSBF
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$26,175	$1,694.09	+$2.3205424011366188e+23M → IXSBF
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$30,133	$1,811.32	+$3.0927990661046884e+27M → IXSBF
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$34,531	$1,927.17	+$3.8524105697352695e+31M → IXSBF
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$39,403	$2,041.08	+$4.484688260147987e+35M → IXSBF
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$44,787	$2,152.59	+$4.879226400974806e+39M → IXSBF

IXSBF vs JEPQ: Complete Analysis 2026

IXSBF — Stock

InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.

Full IXSBF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this IXSBF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IXSBF vs SCHD IXSBF vs JEPI IXSBF vs O IXSBF vs KO IXSBF vs MAIN IXSBF vs XYLD IXSBF vs QYLD IXSBF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.